Meropenem Dosage

This dosage information may not include all the information needed to use Meropenem safely and effectively. See additional information for Meropenem.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Skin and Structure Infection

500 mg IV every 8 hours

Approved indication: As a single agent therapy for treatment of complicated skin and skin structure infections caused by susceptible microorganisms

Usual Adult Dose for Intraabdominal Infection

1 g IV every 8 hours

Approved indication: As a single agent therapy for treatment of complicated intraabdominal infections (including appendicitis and peritonitis) caused by susceptible microorganisms

Usual Adult Dose for Meningitis

(Not approved by FDA)

Infectious Diseases Society of America (IDSA) recommendations: 2 g IV every 8 hours for 7 to 21 days

Comments:
-Recommended as an alternative therapy

Usual Adult Dose for Nosocomial Pneumonia

(Not approved by FDA)

American Thoracic Society, IDSA recommendations: 1 g IV every 8 hours
Duration of therapy: If the causative organism is not P aeruginosa, the duration of therapy should be as short as clinically possible (e.g., as little as 7 days) to reduce the risk of superinfections with resistant organisms.

Comments:
-Initial empiric treatment with broad-spectrum coverage according to the hospital's and/or ICU's antibiogram is recommended if multidrug-resistant organisms are suspected.

Usual Pediatric Dose for Skin and Structure Infection

3 months or older:
Less than 50 kg: 10 mg/kg IV every 8 hours
Maximum dose: 500 mg/dose

50 kg or more: 500 mg IV every 8 hours

Approved indication: As a single agent therapy for treatment of complicated skin and skin structure infections caused by susceptible microorganisms

Usual Pediatric Dose for Intraabdominal Infection

3 months or older:
Less than 50 kg: 20 mg/kg IV every 8 hours
Maximum dose: 1 g/dose

50 kg or more: 1 g IV every 8 hours

Approved indication: As a single agent therapy for treatment of complicated intraabdominal infections (including appendicitis and peritonitis) caused by susceptible microorganisms

Usual Pediatric Dose for Meningitis

3 months or older:
Less than 50 kg: 40 mg/kg IV every 8 hours
Maximum dose: 2 g/dose

50 kg or more: 2 g IV every 8 hours

Comments:
-Effective in eliminating concurrent bacteremia associated with bacterial meningitis.

Approved indication: As a single agent therapy for treatment of bacterial meningitis caused by susceptible microorganisms

Renal Dose Adjustments

Adult patients:
CrCl 26 to 50 mL/min: Recommended dose every 12 hours
CrCl 10 to 25 mL/min: One-half recommended dose every 12 hours
CrCl less than 10 mL/min: One-half recommended dose every 24 hours

Pediatric patients: Data not available

Liver Dose Adjustments

No adjustment recommended.

Dose Adjustments

Pediatric patients: There is limited safety data available to support the use of a 40 mg/kg (maximum of 2 g) bolus dose.

Precautions

Consult WARNINGS section for dosing related precautions.

Dialysis

Hemodialysis, peritoneal dialysis: Data not available

Some experts recommend:
Adults:
Conventional hemodialysis: 500 mg IV every 24 hours; alternatively, a dose of 500 mg to 1 g may be given after each dialysis session

Continuous renal replacement therapy: Clearance may be significantly increased; therefore, dose adjustments may be necessary which should be individualized based on the estimated meropenem clearance. Alternatively, initial doses of 500 mg every 12 hours have been suggested for patients undergoing continuous venovenous hemofiltration, and 750 mg every 8 hours or 1500 mg every 12 hours for patients undergoing continuous venovenous hemodiafiltration.

Other Comments

Administration advice:
-Adults: Meropenem should be given as an IV infusion over approximately 15 to 30 minutes; alternatively, doses of 1 g may be given as an IV bolus injection over approximately 3 to 5 minutes.
-Pediatric patients: Meropenem should be given as an IV infusion over approximately 15 to 30 minutes or as an IV bolus injection over approximately 3 to 5 minutes.

Storage requirements:
-The manufacturer's product information should be consulted.

IV compatibility:
-Compatibility with other drugs has not been established.
-Meropenem should not be mixed with or physically added to solutions containing other drugs.

Monitoring:
-Periodic assessment of organ system functions (including renal, hepatic, and hematopoietic) recommended during prolonged therapy.
-It may be helpful to monitor renal function in elderly patients.

Patient advice:
-Patients should not operate machinery or motorized vehicles until it is reasonable well established that meropenem is well tolerated.

Hide
(web3)